Letter to the Editor
Suspected interaction of oprelvekin (rhIL-11) with a long-acting opioid
Paul Moorehead MD,
Corresponding Author
Paul Moorehead MD
Department of Pediatrics, Division of Pediatric Hematology/Oncology, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
Division of Pediatric Hematology/Oncology, Children's Hospital of Eastern Ontario, Room 5109, 401 Smyth Road, Ottawa, Ontario, Canada K1H 8L1.===
Search for more papers by this author Karen M. Mandel MD,
Karen M. Mandel MD
Department of Pediatrics, Division of Pediatric Hematology/Oncology, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
Search for more papers by this author Donna L. Johnston MD,
Donna L. Johnston MD
Department of Pediatrics, Division of Pediatric Hematology/Oncology, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
Search for more papers by this author
Paul Moorehead MD,
Corresponding Author
Paul Moorehead MD
Department of Pediatrics, Division of Pediatric Hematology/Oncology, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
Division of Pediatric Hematology/Oncology, Children's Hospital of Eastern Ontario, Room 5109, 401 Smyth Road, Ottawa, Ontario, Canada K1H 8L1.===
Search for more papers by this author Karen M. Mandel MD,
Karen M. Mandel MD
Department of Pediatrics, Division of Pediatric Hematology/Oncology, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
Search for more papers by this author Donna L. Johnston MD,
Donna L. Johnston MD
Department of Pediatrics, Division of Pediatric Hematology/Oncology, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
Search for more papers by this author
First published: 09 October 2008
No abstract is available for this article.
REFERENCES
- 1
Reynolds CH.
Clinical efficacy of rhIL-11.
Oncology (Williston Park)
2000;
14:
32–40.
- 2
Gibson PJ,
Vadeboncoeur CM,
Johnston DL.
Relapse of Wilms' tumor 13 years after original diagnosis.
J Pediatr Hematol Oncol
2002;
24:
192–198.
- 3
Ault K,
Mitchell J,
Knowles C.
Recombinant human interleukin eleven (Neumega rhIL-11 growth factor) increases plasma volume and decreases urine-sodium excretion in normal human subjects (abstract).
Blood
1994;
84:
276a.
- 4
Dykstra K,
Rogge H,
Stone A, et al.
Effect of diuretic treatment on rhIL-11-induced salt and water retention (abstract).
Blood
1996;
88:
346a.
- 5
LL Brunton, editor.
Goodman & Gilman's The Pharmacological Basis of Therapeutics,
11th edition.
U.S.A.: McGraw-Hill;
2006.
